Literature DB >> 3694613

Effects of danazol on mineral homeostasis in normal postmenopausal women: preliminary communication.

D W Purdie1, A Hay, S K Abbas.   

Abstract

The effects of danazol on calcium homeostasis in normal postmenopausal women was examined in a 14-day study utilizing a dosage of 800 mg per day. Danazol caused significant falls in plasma ionized calcium and in the fasting urinary calcium/creatinine ratio, indicating inhibition of bone resorption. Retention of phosphate was also observed as expected with this anabolic agent. The plasma total alkaline phosphatase was also depressed by the drug, which had no effect on hepatocellular function as measured by plasma AST. Certain effects induced by treatment with danazol were still apparent two weeks after cessation of treatment. The drug was well tolerated and androgenic side effects were not seen. It is suggested that the minimal dose regimen of danazol which exerts a calcium-sharing effect should be identified, and that this regimen should be considered for use in a prospective study of the effects of danazol on bone mineral content in the postmenopause.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3694613      PMCID: PMC1291087          DOI: 10.1177/014107688708001107

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  6 in total

1.  Replacement estrogens and endometrial cancer.

Authors:  H Jick; R N Watkins; J R Hunter; B J Dinan; S Madsen; K J Rothman; A M Walker
Journal:  N Engl J Med       Date:  1979-02-01       Impact factor: 91.245

2.  Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women.

Authors:  R Lindsay; D M Hart; D Purdie; M M Ferguson; A S Clark; A Kraszewski
Journal:  Clin Sci Mol Med       Date:  1978-02

3.  Danazol--a synthetic steroid derivative with interesting physiologic properties.

Authors:  W P Dmowski; H F Scholer; V B Mahesh; R B Greenblatt
Journal:  Fertil Steril       Date:  1971-01       Impact factor: 7.329

4.  Changes in body composition following therapy of osteoporosis with methandrostenolone.

Authors:  J F Aloia; A Kapoor; A Vaswani; S H Cohn
Journal:  Metabolism       Date:  1981-11       Impact factor: 8.694

5.  Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action.

Authors:  C H Chesnut; J L Ivey; H E Gruber; M Matthews; W B Nelp; K Sisom; D J Baylink
Journal:  Metabolism       Date:  1983-06       Impact factor: 8.694

6.  Early effects of ethinyloestradiol and norethisterone treatment in post-menopausal women on bone resorption and calcium regulating hormones.

Authors:  P L Selby; M Peacock; S A Barkworth; W B Brown; G A Taylor
Journal:  Clin Sci (Lond)       Date:  1985-09       Impact factor: 6.124

  6 in total
  1 in total

1.  Danazol-induced hypercalcaemia in alphacalcidol-treated hypoparathyroidism.

Authors:  N C Hepburn; L A Abdul-Aziz; R Whiteoak
Journal:  Postgrad Med J       Date:  1989-11       Impact factor: 2.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.